Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h

Aliment Pharmacol Ther. 2006 Apr 1;23(7):975-84. doi: 10.1111/j.1365-2036.2006.02849.x.

Abstract

Background: Attainment of intragastric pH < 6.0 may require high-dose continuously infused proton pump therapy.

Aim: To assess the pharmacokinetic and pharmacodynamic dose-responses of continuous infusion regimens of lansoprazole.

Methods: Healthy adult subjects were assigned to lansoprazole 60-mg intravenous bolus, followed by 6-mg/h continuous infusion; a 90-mg intravenous bolus followed by 6-, 7.5-, or 9-mg/h continuous infusion; or placebo.

Results: Mean intragastric pH values for lansoprazole regimens ranged from 4.8 to 5.2 (0-24 h), 5.5 to 6.0 (>24 to 48 h) and 5.2 to 5.6 (0-48 h). Within these three intervals, the percentages of time intragastric pH exceeded 4, 5 and 6 ranged from 65% to 96%, 54% to 88% and 30% to 61% respectively. Pharmacokinetic parameters were dose-independent with steady-state plasma concentrations achieved within 6-12 h postdose and maintained over 48 h. The mean systemic clearance of lansoprazole was lower in CYP2C19 heterozygous metabolizers than in homozygous extensive metabolizers (9.2 vs. 16.5 L/h), with substantial variability resulting in overlapping ranges of clearance values for both subpopulations. All lansoprazole regimens were well-tolerated.

Conclusions: Lansoprazole administered as a 60-mg intravenous bolus followed by 6-mg/h continuous infusion produced intragastric pH effects comparable with those of higher dosage regimens.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Adolescent
  • Adult
  • Anti-Ulcer Agents / administration & dosage*
  • Anti-Ulcer Agents / adverse effects
  • Anti-Ulcer Agents / pharmacokinetics
  • Aryl Hydrocarbon Hydroxylases / metabolism
  • Cytochrome P-450 CYP2C19
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Gastric Acidity Determination
  • Genotype
  • Humans
  • Hydrogen-Ion Concentration / drug effects
  • Infusions, Intravenous
  • Lansoprazole
  • Male
  • Metabolic Clearance Rate
  • Middle Aged
  • Mixed Function Oxygenases / metabolism
  • Omeprazole / administration & dosage
  • Omeprazole / adverse effects
  • Omeprazole / analogs & derivatives*
  • Omeprazole / pharmacokinetics
  • Proton Pump Inhibitors
  • Stomach / drug effects

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents
  • Proton Pump Inhibitors
  • Lansoprazole
  • Mixed Function Oxygenases
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Omeprazole